Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Subject is of Chinese descent
- Subject is in good health
- Subject is a non-smoker
Exclusion Criteria:
- Subject has a history of stroke or chronic seizures
- Subject has a history of cancer
- Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850
2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC
3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500
4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 500 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin Co-administration of 50 mg sitagliptin and 500mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 500mg metformin
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 500 mg metformin Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet